Perspective and Assertio Set for Pivotal Q4 Earnings Amid Sector Shifts
Perspective Therapeutics and Assertio Holdings are preparing to report Q4 2025 results, with investors focused on Perspective's radiopharmaceutical pipeline and Assertio's commercial execution of its expanded portfolio. These reports will provide critical updates on clinical milestones and revenue diversification strategies for both specialty players.